Pediatric antiretroviral therapy

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 12, 2010, Pages 1381-1402

  Cadilla, Adriana ^a   Qureshi, Nadia ^a   Johnson, Daniel C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

adherence; antiretroviral therapy; drug resistance; non nucleoside reverse transcriptase inhibitor; nucleoside reverse transcriptase inhibitor; pediatric HIV infection; protease inhibitor

Indexed keywords

ABACAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; ENFUVIRTIDE; ENTECAVIR; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ASTHENIA; BEDTIME DOSAGE; BLOOD TOXICITY; BODY FAT DISTRIBUTION; BONE DENSITY; BRAIN TOXICITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONDOM; CONFUSION; CONTRACEPTION; COUGHING; CROSS RESISTANCE; DEPIGMENTATION; DIARRHEA; DISEASE COURSE; DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FATTY LIVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GLYCEMIC CONTROL; HALLUCINATION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; INJECTION SITE REACTION; INSOMNIA; JUVENILE DIABETES MELLITUS; LACTIC ACIDOSIS; LIFE CYCLE; LIPOATROPHY; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; MYOPATHY; MYOSITIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NIGHTMARE; NOSE DISEASE; ORAL PARESTHESIA; PANCREATITIS; PEDIATRICS; PERIPHERAL NEUROPATHY; PHENOTYPE; PR INTERVAL; PRURITUS; REVERSE TRANSCRIPTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VIRION; VIRUS CAPSID; VIRUS LOAD; VIRUS RESISTANCE; VOMITING; WEAKNESS;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 78650215858     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.127     Document Type: Review

References (145)

1. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defc. Syndr. 29(5), 484-494 (2002).
2. Lindegren ML, Byers RH Jr, Thomas P et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 282(6), 531-538 (1999).
3. de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry JAMA 284(2), 190-197 (2000).
4. Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N. Engl. J. Med. 345(21), 1522-1528 (2001).
5. Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin. Infect. Dis. 45(7), 918-924 (2007).
6. Patel K, Hernan MA, Williams PL et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin. Infect. Dis. 46(4), 507-515 (2008). (Pubitemid 351263487)
7. Brady MT, Oleske JM, Williams PL et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J. Acquir. Immune Defc. Syndr. 53(1), 86-94 (2010).
8. Furman PA, Fyfe JA, St Clair MH et al. Phosphorylation of 3-azido-3-deoxythymidine and selective interaction of the 5-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl Acad. Sci. USA. 83(21), 8333-8337 (1986).
9. Birkus G, Hitchcock MJ, Cihlar T Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46(3), 716-723 (2002). (Pubitemid 34157656)
10. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354(9184), 1112-1115 (1999).
11. de Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16(2), 125-157 (1996).
12. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect. Dis. 7(11), 733-738 (2007).
13. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 31(4), 692-704 (2009).
14. Konigs C, Feiterna-Sperling C, Esposito S. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. Presented at: 16th Conference on Retroviruses and Opportunistic Infections, Montereal, Canada, 8-11 February 2009.
15. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J. Acquir. Immune Defc. Syndr. 35(5), 538-539 (2004).
16. Lewis JS, 2nd, Terriff CM, Coulston DR, Garrison MW. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin. Ther. 19(2), 187-214 (1997).
17. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J. Acquir. Immune Defc. Syndr. 27(1), 30-34 (2001).
18. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 350(9079), 713-714 (1997).
19. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann. Intern. Med. 127(10), 948 (1997).
20. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann. Intern. Med. 127(10), 947 (1997).
21. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and effcacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369(9569), 1261-1269 (2007).
22. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defc. Syndr. 46(2), 125-133 (2007).
23. Wiznia A, Samson P, Acosta E et al. Safety and effcacy of raltegravir (RAL) in pediatric HIV infection. Preliminary analysis from IMPAACT P1066 [Poster]. Presented at: CROI 2009. Montreal, Canada, 8-11 February 2009.
24. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49(11), 4721-4732 (2005).
25. Lazzarin A, Campbell T, Clotet B et al. Effcacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581), 39-48 (2007).
26. Salzberger B, Daumer M, Gute P et al. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Eur. J. Med. Res. 12(3), 93-102 (2007).
27. Church JA, Cunningham C, Hughes M et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. 21(7), 653-659 (2002).
28. Menson EN, Walker AS, Sharland M et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Br. Med. J. 332(7551), 1183-1187 (2006).
29. Paediatric European Network for Treatment of AIDS. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 12(14), F151-F160 (1998).
30. McKinney RE Jr, Johnson GM, Stanley K et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J. Pediatr. 133(4), 500-508 (1998).
31. Resino S, Resino R, Micheloud D et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin. Infect. Dis. 42(6), 862-869 (2006).
32. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br. Med. J. 327(7422), 1019 (2003).
33. McConnell MS, Byers RH, Frederick T et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J. Acquir. Immune Defc. Syndr. 38(4), 488-494 (2005).
34. Nachman SA, Lindsey JC, Moye J et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 24(4), 352-357 (2005).
35. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr. Infect. Dis. J. 22(7), 635-641 (2003).
36. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39(5), 725-731 (2004).
37. Persaud D, Siberry GK, Ahonkhai A et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 78(2), 968-979 (2004).
38. Pomerantz RJ. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS 15(10), 1201-1211 (2001).
39. Saitoh A, Hsia K, Fenton T et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J. Infect. Dis. 185(10), 1409-1416 (2002).
40. Diaz C, Hanson C, Cooper ER et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J. Acquir. Immune. Defc. Syndr. Hum. Retrovirol. 18(3), 221-228 (1998).
41. Newell ML, Coovadia H, Cortina- Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled ana lysis. Lancet 364(9441), 1236-1243 (2004).
42. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-ana lysis. Lancet 362 (9396), 1605-1611 (2003).
43. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359(21), 2233-2244 (2008).
44. Abrams EJ, Wiener J, Carter R et al. Maternal health factors and early pediatric antiretroviral therapy infuence the rate of perinatal HIV-1 disease progression in children. AIDS 17(6), 867-877 (2003).
45. Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J. Infect. Dis. 197(3), 398-404 (2008).
46. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 20(9), 1289-1294 (2006).
47. Wongsawat J, Puthanakit T, Kanjanavanit S et al. CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 29(10), 966-968 (2010).
48. Hecht FM, Grant RM. Resistance testing in drug-naive HIV-infected patients: is it time? Clin. Infect. Dis. 41(9), 1324-1325 (2005).
49. Persaud D, Palumbo P, Ziemniak C et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J. Infect. Dis. 195(10), 1402-1410 (2007).
50. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354(3), 251-260 (2006).
51. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15(2), 247-277 (2002).
52. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17(5), 138-145 (2009).
53. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2004. Top. HIV Med. 12(4), 119-124 (2004).
54. DeJesus E, Herrera G, Teoflo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39(7), 1038-1046 (2004).
55. Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 21(8), 947-955 (2007)
56. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir. Ther. 15(3), 297-305 (2010).
57. Bergshoeff A, Burger D, Verweij C et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplifcation of combination treatment in HIV-1-infected children (PENTA-13). Antivir. Ther. 10(2), 239-246 (2005).
58. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
59. Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the effcacy of frst-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression ana lysis of 12 clinical trials in 5168 patients. HIV Med. 10(9), 527-535 (2009).
60. Sax PE, Tierney C, Collier AC et al. Abacavir-lamivudine versus tenofovir- emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 361(23), 2230-2240 (2009).
61. McKinney RE Jr, Rodman J, Hu C et al. Long-term safety and effcacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 120(2), e416-e423 (2007).
62. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res. Hum. Retroviruses. 16(5), 415-421 (2000).
63. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J. Acquir. Immune Defc. Syndr. 40(4), 448-450 (2005).
64. Hazra R, Balis FM, Tullio AN et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 48(1), 124-129 (2004).
65. Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118(3), e711-e718 (2006).
66. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J. Pediatr. 152(4), 582-584 (2008).
67. Arribas JR, Pozniak AL, Gallant JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week ana lysis. J. Acquir. Immune Defc. Syndr. 47(1), 74-78 (2008).
68. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr. Nephrol. 21(7), 1034-1036 (2006).
69. Judd A, Boyd KL, Stohr W et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24(4), 525-534 (2010).
70. Papaleo A, Warszawski J, Salomon R et al. Increased b-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr. Infect. Dis. J. 26(10), 949-951 (2007).
71. Van Dyke RB, Wang L, Williams PL. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J. Infect. Dis. 198(11), 1599-1608 (2008).
72. Falco V, Rodriguez D, Ribera E et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin. Infect. Dis. 34(6), 838-846 (2002).
73. Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16(18), 2447-2454 (2002).
74. Shafer RW, Smeaton LM, Robbins GK et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349(24), 2304-2315 (2003).
75. Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different fndings. HIV Clin. Trials 4(1), 11-19 (2003).
76. Balestre E, Dupon M, Capdepont S et al. Virological response to HIV-1 nucleoside/ nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. J. Clin. Virol. 36(2), 95-99 (2006).
77. Gallant JE, Rodriguez AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192(11), 1921-1930 (2005).
78. Gerstoft J, Kirk O, Obel N et al. Low effcacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 17(14), 2045-2052 (2003).
79. Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350(18), 1850-1861 (2004).
80. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV- infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir df. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004.
81. van Leeuwen R, Katlama C, Murphy RL et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17(7), 987-999 (2003).
82. Saavedra J, McCoig C, Mallory M et al. Clinical experience with triple nucleoside (NRTI) combination ZDV/3TC/abacavir (ABC) as initial therapy in HIV-infected children. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16-19 December 2001.
83. Wells C, Sharland M, Smith C et al. Triple nucleoside analogue therapy with zidovudine (AZT), lamivudine (3TC) and abacavir (ABC) in the paediatric HIV london south network (PHILS-NET) cohort. Presented at: XIV International Conference on AIDS. Barcelona, Spain, 7-12 July 2002.
84. Starr SE, Fletcher C V, Spector SA et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 21(7), 659-663 (2002).
85. Fraaij PL, Neubert J, Bergshoeff AS et al. Safety and effcacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir. Ther. 9(2), 297-299 (2004).
86. Funk MB, Notheis G, Schuster T et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur. J. Med. Res. 10(12), 503-508 (2005).
87. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. 5(2), 105-109 (2004).
88. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
89. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J. Acquir. Immune Defc. Syndr. 35(5), 492-502 (2004).
90. Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J. Acquir. Immune Defc. Syndr. 46(2), 187-193 (2007).
91. Taylor P, Worrell C, Steinberg SM et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 114(2), e235-e242 (2004).
92. Chadwick EG, Capparelli EV, Yogev R et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 22(2), 249-255 (2008).
93. De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M. Different kinetics of immunologic recovery using nelfnavir or lopinavir/ ritonavir-based regimens in children with perinatal HIV-1 infection. Int. J. Immunopathol. Pharmacol. 18(4), 729-735 (2005).
94. Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22(3), 216-224 (2003).
95. Stebbing J, Nathan B, Jones R et al. Virological failure and subsequent resistance profles in individuals exposed to atazanavir. AIDS 21(13), 1826-1828 (2007).
96. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers T W. Long-term experience with combination antiretroviral therapy that contains nelfnavir for up to 7 years in a pediatric cohort. Pediatrics 117(3), e528-e536 (2006).
97. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfnavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359(9308), 733-740 (2002).
98. Funk MB, Linde R, Wintergerst U et al. Preliminary experiences with triple therapy including nelfnavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 13(13), 1653-1658 (1999).
99. Krogstad P, Lee S, Johnson G et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfnavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin. Infect. Dis. 34(7), 991-1001 (2002).
100. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510), 123-126 (1995).
101. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373(6510), 117-122 (1995).
102. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 242(4882), 1168-1171 (1988).
103. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 242(4882), 1171-1173 (1988).
104. Dykes C, Demeter LM. Clinical signifcance of human immunodeficiency virus type 1 replication ftness. Clin. Microbiol. Rev. 20(4), 550-578 (2007).
105. Kijak GH, Avila MM, Salomon H. Mother-to-child transmission of drug-resistant HIV. Drug Resist. Updat. 4(1), 29-37 (2001).
106. Little SJ, Frost SD, Wong JK et al Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol 82(11), 5510-5518 (2008).
107. Little SJ, Holte S, Routy JP et al Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347(6), 385-394 (2002).
108. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J. Infect. Dis. 201(9), 1303-1307 (2010).
109. Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47(2), 266-285 (2008).
110. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defc. Syndr. 30(1), 105-110 (2002).
111. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 17(4), 169-177 (2003).
112. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 119(6), e1371-e1383 (2007).
113. Hammami N, Nostlinger C, Hoeree T, Lefevre P, Jonckheer T, Kolsteren P. Integrating adherence to highly active antiretroviral therapy into children's daily lives: a qualitative study. Pediatrics 114(5), e591-e597 (2004).
114. Malee K, Williams PL, Montepiedra G et al. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J. Pediatr. Psychol. 34(2), 164-175 (2009).
115. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23(11), 1035-1041 (2004).
116. Marhefka SL, Tepper VJ, Brown JL, Farley JJ. Caregiver psychosocial characteristics and children's adherence to antiretroviral therapy. AIDS Patient Care STDS 20(6), 429-437 (2006).
117. Williams PL, Storm D, Montepiedra G et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 118(6), e1745-1757 (2006).
118. Merzel C, Vandevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS 22(12), 977-987 (2008).
119. Battles HB, Wiener LS. From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV. J. Adolesc. Health 30(3), 161-168 (2002).
120. Saitoh A, Foca M, Viani RM et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 121(3), e513-e521 (2008).
121. Wagner GJ, Kanouse DE, Golinelli D et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS 20(9), 1295-1302 (2006).
122. Armstrong AW, Watson AJ, Makredes M, Frangos JE, Kimball AB, Kvedar JC. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. Arch. Dermatol. 145(11), 1230-1236 (2009).
123. Lester RT, Mills EJ, Kariri A et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials 10, 87 (2009).
124. De Costa A, Shet A, Kumarasamy N et al. Design of a randomized trial to evaluate the infuence of mobile phone reminders on adherence to first line antiretroviral treatment in South India - the HIVIND study protocol. BMC Med. Res. Methodol. 10, 25 (2010).
125. Bikaako-Kajura W, Luyirika E, Purcell DW et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav. 10(Suppl. 4), S85-S93 (2006).
126. Wiener L, Mellins CA, Marhefka S, Battles HB. Disclosure of an HIV diagnosis to children: history, current research, and future directions. J. Dev. Behav. Pediatr. 28(2), 155-166 (2007).
127. Domek GJ. Debunking common barriers to pediatric HIV disclosure. J. Trop. Pediatr. DOI: 10.1093/tropej/fmq013 (2010) (Epub ahead of print).
128. Lesch A, Swartz L, Kagee A et al. Paediatric HIV/AIDS disclosure: towards a developmental and process-oriented approach. AIDS Care 19(6), 811-816 (2007).
129. Butler AM, Williams PL, Howland LC, Storm D, Hutton N, Seage GR 3rd. Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics 123(3), 935-943 (2009).
130. Souza E, Santos N, Valentini S, Silva G, Falbo A. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure. J. Trop. Pediatr. (2010).
131. Riekert K, Wiener L, Battles H. Prediction of psychological distress in school-age children with HIV. Child. Health Care 28(3), 201-220 (1999).
132. Lester P, Chesney M, Cooke M et al. When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. J. Acquir. Immune Defc. Syndr. 31(3), 309-317 (2002).
133. Sherman BF, Bonanno GA, Wiener LS, Battles HB. When children tell their friends they have AIDS: possible consequences for psychological well-being and disease progression. Psychosom. Med. 62(2), 238-247 (2000).
134. Michaud PA, Suris JC, Thomas LR, Kahlert C, Rudin C, Cheseaux JJ. To say or not to say: a qualitative study on the disclosure of their condition by human immunodeficiency virus-positive adolescents. J. Adolesc. Health 44(4), 356-362 (2009).
135. Ezeanolue EE, Wodi A P, Patel R, Dieudonne A, Oleske JM. Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center. J. Adolesc. Health 38(6), 719-725 (2006).
136. Wiener LS, Battles HB, Heilman N, Sigelman CK, Pizzo PA. Factors associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr. AIDS HIV Infect. 7(5), 310-324 (1996).
137. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam. Plann. Perspect. 31(6), 272-279 (1999).
138. Mishell D. Family planning: contraception, sterilization, and pregnancy termination. In: Comprehensive Gynecology (5th Edition). Katz VL, Lentz GM, Lobo RA, Gershenson DM (Eds). Mosby Elsevier, PA, USA, 275-325 (2007).
139. Mildvan D, Yarrish R, Marshak A et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. J. Acquir. Immune Defc. Syndr. 29(5), 471-477 (2002).
140. Ouellet D, Hsu A, Qian J et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46(2), 111-116 (1998).
141. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 75(Suppl. 6), S8-S11 (2007).
142. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J. Pediatr. 129(5), 671-676 (1996).
143. Zhou T, Georgiev I, Wu X et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329(5993), 811-817 (2010).
144. Tebas P, Stein D, Zifchak L et al. Prolonged control of viremia after transfer of autologous CD4 cells genetically modifed with a lentiviral vector expressing long antisense to HIV env (VRX496). Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
145. Smith PF, Ogundele A, Forrest A et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 51(10), 3574-3581 (2007)